This website uses cookies

We use cookies to ensure you get the best experience. Check our Privacy Policy

Manage Cookies

Manage Cookies

You can choose to enable or disable some or all of these cookies but disabling some of them may affect your browsing experience.

Advertisement

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously

Analytics

Analytical cookies are used to understand how visitors interact with the website.

Functional

Functional cookies help perform certain functionalities like collecting feedback, and other third-party features.

Performance

Performance cookies are used to understand and analyze the key performance indexes of the website.

tm logo
OKITRUZ
REGISTERED

on 01 Jun 2022

Last Applicant/ Owned by

GLAXO GROUP LIMITED

GSK Medicines Research CentreGunnels Wood Road, Stevenage SG1 2NY

GB

Serial Number

2020726 filed on 19th Feb 2020

Registration Number

TMA1130661 registered on 01st Jun 2022

Registration expiry Date

19th Feb 2030

Correspondent Address

World Exchange Plaza100 Queen Street, Suite 1300Ottawa

ONTARIO

CA

K1P1J9

OKITRUZ

Trademark usage description

pharmaceutical and medicinal preparations and substances excluding anti-inflammatory, antipyretic and analgesic preparations and substances, namely, p Read More

Classification Information


Class [005]
Pharmaceutical and medicinal preparations and substances excluding anti-inflammatory, antipyretic and analgesic preparations and substances, namely, pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficiency virus (HIV), human papilloma virus, respiratory syncytial virus, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders and their symptoms; pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely immunosuppressants; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment of viral conditions namely human immunodeficiency virus (HIV), HPV, RSV, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders namely disorders of the endocrine system, namely growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascular, cardiopulmonary, cardio-renal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain, bone pain and fatigue; pharmaceutical preparations for the treatment of blood-related diseases and disorders namely thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle-cell disease and disorders, anemias, sepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, joint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and skin structure infections namely bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema and sexually transmitted diseases; pharmaceutical preparations for the treatment of hormonal related diseases and disorders namely hypogonadism, testosterone, androgen and estrogen disorders; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders namely irritable bowel disorders and symptoms, digestive disorders and acid-related disorders, namely, acid reflux and gastroesophageal reflux disease; pharmaceutical preparations for the treatment of sexual dysfunction namely erectile dysfunction, male and female sexual dysfunction disorders namely arousal disorder, pain disorder, desire disorder and orgasm disorder; pharmaceutical preparations for the treatment of genitourinary diseases namely urological diseases and disorders; pharmaceutical preparations for the treatment of gynaecological diseases and disorders namely amenorrhoea, dysmenorrheal and infertility; pharmaceutical hormonal preparations namely corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of sexually transmitted diseases, inflammatory pelvic diseases, vasomotor and menopausal symptoms, endometriosis and uterine fibroids, Leiomyoma, endourological disorders and for the removal of renal calculi and the treatment of nephrolithiasis and urolithiasis, pre-eclampsia and pre-term labour; pharmaceutical preparations for the treatment of prostatitis, nephritis, cystitis, vaginitis, renal disease; pharmaceutical preparations for the treatment of premenstrual dysphoric disorder, premenstrual syndrome, male hypogonadism and hormonal disorders namely polycystic ovary syndrome; pharmaceutical preparations for the treatment of hepatological related diseases namely hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibroids, and cirrhosis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia (male pattern baldness); pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and psychoses; pharmaceutical preparations for the treatment of damaged skin and tissue namely bee stings, sunburn, rashes, sores, corns, calluses and acne; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; Allergy medications; Vaccines namely prophylactic and therapeutic vaccines for humans; pharmaceutical preparations for the treatment of neurological diseases and disorders namely Parkinsons Disease, Alzheimers Disease, Huntingtons Disease, dementia, migraine, cerebral palsy, brain injury, spinal cord injury, seizure disorders, epilepsy, restless legs syndrome, pain, neuropathic pain, fibromyalgia, stroke, multiple sclerosis, insomnia; pharmaceutical preparations for the treatment of central nervous system diseases and disorders namely central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, depression and anxiety and their related disorders namely schizophrenia and psychoses; pharmaceutical preparations for the treatment of muscular dystrophy.


Classification kind code

11

Mark Details


Serial Number

2020726

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 22
on 30th Jul 2021
Search Recorded
Submitted for opposition 20
on 30th Jul 2021
Examiner's First Report
Submitted for opposition 256
on 02th Feb 2021
Notification of Possible Opposition Sent
Submitted for opposition 48
on 13th Aug 2020
Agent Changed
Submitted for opposition 236
on 11th Aug 2020
Partial Withdrawal - Madrid Protocol
Submitted for opposition 257
on 02th Apr 2020
Designation Notification - Madrid Protocol
Submitted for opposition 1
on 01st Apr 2020
Created
Submitted for opposition 31
on 01st Apr 2020
Formalized
Submitted for opposition 30
on 19th Feb 2020
Filed
Submitted for opposition 228
on 19th Feb 2020
International Registration